Royalty Pharma plc

NasdaqGS:RPRX

Sector

🏥 Health Care

Industries

🧬 Biotechnology

💰 Investment Banking & Asset Management

💊 Pharmaceuticals

💼 Private Equity

💰 Venture Capital

Location

United States

Market Cap

USD 21.58 B

Share Price

USD 37.58

Avg Daily Volume

4,285,775

Change (1 day)

1.54%

Change (1 year)

43.71%

Change (YTD)

47.32%

Royalty Pharma plc EBIT Margin for the Trailing 12 Months (TTM) ending June 30, 2025: 82.10%

Royalty Pharma plc EBIT Margin is 82.10% for the Trailing 12 Months (TTM) ending June 30, 2025, a 1,130.20% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

Royalty Pharma plc EBIT Margin for the Trailing 12 Months (TTM) ending June 30, 2024 was 6.67%, a -70.77% change year over year.
Royalty Pharma plc EBIT Margin for the Trailing 12 Months (TTM) ending June 30, 2023 was 22.83%, a -47.25% change year over year.
Royalty Pharma plc EBIT Margin for the Trailing 12 Months (TTM) ending June 30, 2022 was 43.28%, a -48.24% change year over year.
Royalty Pharma plc EBIT Margin for the Trailing 12 Months (TTM) ending June 30, 2021 was 83.63%, a -38.64% change year over year.